Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18th year of age completed)~* Signed and dated written informed consent form prior to any procedures related to this protocol.~* Histologically confirmed advanced clear cell renal cancer.~* Measurable disease.~* Failure of first line anti-VEGF treatment.~* Performance status 0-2, according to Eastern Cooperative Oncology Group (ECOG) .~* Satisfactory hematological parameters:~  * White blood cell count \> 4000 mm3.~ * Platelet count 100000/mm3.~ * Neutrophil blood cell count \> 1200/ mm3 .~ * Hemoglobin \> 9,0 g/dL (can be achieved with red blood cell transfusion).~* Satisfactory biochemical parameters:~  * Serum creatinine \< 2 x Upper Limit of Normal(ULN)~ * Aspartate Aminotransferase (AST)\<2,5 x ULN~ * Alanine Transaminase (ALT)\< 2,5 x ULN.~ * Bilirubin \<2 x ULN~* (For female patients) Absence of pregnancy (negative pregnancy test for women of reproductive age before enrollment).~* (For female patients) Non-lactating women.~* Use of efficient contraceptive measures (women and men) to prevent possible pregnancy of female patient or female partner of a male patient during treatment and until 6 months after the end of treatment.~Exclusion Criteria:~* Prior treatment with mTOR inhibitor.~* Major surgery (including open biopsy) or insufficient recovery or existence of major trauma within 4 weeks before enrollment.~* Uncontrolled hypertension.~* Active infection requiring systemic treatment within 4 weeks prior to enrollment.~* Minor surgery (for instance, catheter placement) within 2 days before enrollment.~* Scheduled major surgery within the treatment period.~* Medical history in the last 6 months prior to enrollment of significant cardiovascular disease, diabetes, cardiac infarction, unstable angina, uncontrolled arrhythmia or significant heart failure.~* Indications of uncontrolled metastases or disease progression in CNS lesions (the suspicion of uncontrolled metastases or disease progression should be eliminated by imaging techniques within 14 days prior to enrollment).~* Medical history in the last 5 years prior to enrollment of any other malignancies (excluding the basal or squamous skin cell carcinoma or in situ carcinoma of the cervix).~* History of non-healing wound including active gastric ulcer.~* History of fistula in the last 6 months prior to enrollment.~* History of gastrointestinal perforations.~* Patient incapacity (for psychiatric or social reasons) to conform with the protocol.~* History of hemorrhagic predisposition.~* History of hypersensitivity to the medications under investigation.~* Significant proteinurea.~* Prior immunotherapy within 4 weeks prior to enrollment.~* Prior radiation treatment within 2 weeks prior to enrollment.~* Concomitant medication with inducers or strong inhibitors of the coenzyme CYP3A4 (see Appendix 5 for an indicative list of active compounds).~* Concurrent participation in other interventional clinical trials with investigational medicinal products.~* History of chronic interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab combined with temsirolimus (Type: EXPERIMENTAL): Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).